USD
$0.00
(0.00%
)At Close (As of Sep 15, 2025)
$61.05B
Market Cap
-
P/E Ratio
-2.47
EPS
$484.21
52 Week High
$205.87
52 Week Low
HEALTHCARE
Sector
Field | Value (USD) |
---|---|
Gross Profit | $1.9B |
Total Revenue | $2.2B |
Cost Of Revenue | $323M |
Costof Goods And Services Sold | $323M |
Operating Income | -$177M |
Selling General And Administrative | $976M |
Research And Development | $1.1B |
Operating Expenses | $2.1B |
Investment Income Net | - |
Net Interest Income | -$20M |
Interest Income | $122M |
Interest Expense | $142M |
Non Interest Income | - |
Other Non Operating Income | - |
Depreciation | - |
Depreciation And Amortization | $57M |
Income Before Tax | -$377M |
Income Tax Expense | -$99M |
Interest And Debt Expense | - |
Net Income From Continuing Operations | -$278M |
Comprehensive Income Net Of Tax | - |
Ebit | -$236M |
Ebitda | -$179M |
Net Income | -$278M |
Field | Value (USD) |
---|---|
Total Assets | $4.2B |
Total Current Assets | $3.3B |
Cash And Cash Equivalents At Carrying Value | $966M |
Cash And Short Term Investments | $966M |
Inventory | $79M |
Current Net Receivables | $405M |
Total Non Current Assets | $945M |
Property Plant Equipment | - |
Accumulated Depreciation Amortization Ppe | - |
Intangible Assets | - |
Intangible Assets Excluding Goodwill | - |
Goodwill | - |
Investments | - |
Long Term Investments | - |
Short Term Investments | $1.7B |
Other Current Assets | $117M |
Other Non Current Assets | - |
Total Liabilities | $4.2B |
Total Current Liabilities | $1.2B |
Current Accounts Payable | $88M |
Deferred Revenue | - |
Current Debt | - |
Short Term Debt | $42M |
Total Non Current Liabilities | $3B |
Capital Lease Obligations | $271M |
Long Term Debt | $1B |
Current Long Term Debt | - |
Long Term Debt Noncurrent | - |
Short Long Term Debt Total | $1.3B |
Other Current Liabilities | $1B |
Other Non Current Liabilities | $1.7B |
Total Shareholder Equity | $67M |
Treasury Stock | - |
Retained Earnings | -$7.3B |
Common Stock | $1.3M |
Common Stock Shares Outstanding | $128M |
Field | Value (USD) |
---|---|
Operating Cashflow | -$8.3M |
Payments For Operating Activities | - |
Proceeds From Operating Activities | - |
Change In Operating Liabilities | - |
Change In Operating Assets | - |
Depreciation Depletion And Amortization | $57M |
Capital Expenditures | $34M |
Change In Receivables | - |
Change In Inventory | $14M |
Profit Loss | - |
Cashflow From Investment | -$117M |
Cashflow From Financing | $294M |
Proceeds From Repayments Of Short Term Debt | - |
Payments For Repurchase Of Common Stock | - |
Payments For Repurchase Of Equity | - |
Payments For Repurchase Of Preferred Stock | - |
Dividend Payout | - |
Dividend Payout Common Stock | - |
Dividend Payout Preferred Stock | - |
Proceeds From Issuance Of Common Stock | - |
Proceeds From Issuance Of Long Term Debt And Capital Securities Net | - |
Proceeds From Issuance Of Preferred Stock | - |
Proceeds From Repurchase Of Equity | - |
Proceeds From Sale Of Treasury Stock | - |
Change In Cash And Cash Equivalents | - |
Change In Exchange Rate | - |
Net Income | -$278M |
Field | Value (USD) |
---|---|
Gross Profit | $1.9B |
Total Revenue | $2.2B |
Cost Of Revenue | $323M |
Costof Goods And Services Sold | $323M |
Operating Income | -$177M |
Selling General And Administrative | $976M |
Research And Development | $1.1B |
Operating Expenses | $2.1B |
Investment Income Net | - |
Net Interest Income | -$20M |
Interest Income | $122M |
Interest Expense | $142M |
Non Interest Income | - |
Other Non Operating Income | - |
Depreciation | - |
Depreciation And Amortization | $57M |
Income Before Tax | -$377M |
Income Tax Expense | -$99M |
Interest And Debt Expense | - |
Net Income From Continuing Operations | -$278M |
Comprehensive Income Net Of Tax | - |
Ebit | -$236M |
Ebitda | -$179M |
Net Income | -$278M |
Sector: HEALTHCARE
Industry: BIOTECHNOLOGY
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.